Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer-related mortality worldwide.[1], [2] Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the prognosis of patients with advanced lung adenocarcinoma, particularly those with EGFR gene mutations.[3], [4]. This evidence concerns the gene EGFR and lung cancer.